References
- Zitvogel L, Tesniere A and Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715-727 https://doi.org/10.1038/nri1936
- Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 https://doi.org/10.1126/science.1129139
- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986) Two types of murine helper T cell clone. I. definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348-2357
- Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10, 490-500 https://doi.org/10.1038/nri2785
- O'Sullivan KE, Phelan JJ, O'Hanlon C, Lysaght J, O'Sullivan JN and Reynolds JV (2014) The role of inflammation in cancer of the esophagus. Expert Rev Gastroenterol Hepatol 8, 749-760 https://doi.org/10.1586/17474124.2014.913478
- Tosello-Trampont A, Surette FA, Ewald SE and Hahn YS (2017) Immunoregulatory role of NK Cells in tissue inflammation and regeneration. Front Immunol 8, 301
- Yadav D and Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252-1261 https://doi.org/10.1053/j.gastro.2013.01.068
- Freeman HJ (2008) Colorectal cancer risk in Crohn's disease. World J Gastroenterol 14, 1810-1811 https://doi.org/10.3748/wjg.14.1810
- Warren JR (2000) Gastric pathology associated with Helicobacter pylori. Gastroenterol Clin North Am 29, 705-751 https://doi.org/10.1016/S0889-8553(05)70139-4
- Noto JM and Peek RM Jr (2012) Helicobacter pylori: an overview. Methods Mol Biol 921, 7-10 https://doi.org/10.1007/978-1-62703-005-2_2
- Sakitani K, Hirata Y, Hayakawa Y et al (2012) Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect Immun 80, 3795-3803 https://doi.org/10.1128/IAI.00637-12
- Seo EH, Kang J, Kim KH et al (2008) Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 18, 1606-1612
- Khawar MB, Abbasi MH and Sheikh N (2016) IL-32: A Novel Pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediators Inflamm 2016, 8413768
- Yan H, He D, Huang X et al (2018) Role of interleukin-32 in cancer biology. Oncol Lett 16, 41-47
-
Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB and Joosten LA (2011) Inflammationdependent secretion and splicing of IL-
$32{\gamma}$ in rheumatoid arthritis. Proc Natl Acad Sci U S A 108, 4962-4967 https://doi.org/10.1073/pnas.1016005108 - Heinhuis B, Plantinga TS, Semango G et al (2016) Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis 37, 197-205 https://doi.org/10.1093/carcin/bgv172
- Sloot YJE SJ, Joosten LAB, Netea-Maier RT (2018) Insights into the role of IL-32 in cancer. Semin Immunol 38, 24-32 https://doi.org/10.1016/j.smim.2018.03.004
- Wang S, Chen F and Tang L (2015) IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett 9, 305-307 https://doi.org/10.3892/ol.2014.2641
- Taguchi A, Ohmiya N, Shirai K et al (2005) Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 14, 2487-2493 https://doi.org/10.1158/1055-9965.EPI-05-0326
- Wang YM, Li ZX, Tang FB et al (2016) Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol 37, 2233-2242 https://doi.org/10.1007/s13277-015-4022-x
- Tsai CY, Wang CS, Tsai MM et al (2014) Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res 20, 2276-2288 https://doi.org/10.1158/1078-0432.CCR-13-1221
- Ishigami S, Arigami T, Uchikado Y et al (2013) IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30, 472 https://doi.org/10.1007/s12032-013-0472-4
- Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU and Vatansever S (2006) Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. Tumour Biol 37, 405-412
- Chang WJ, Du Y, Zhao X, Ma LY and Cao GW (2014) Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 20, 4586-4596 https://doi.org/10.3748/wjg.v20.i16.4586
- Nishida A, Andoh A, Inatomi O and Fujiyama Y (2009) Interleukin-32 expression in the pancreas. J Biol Chem 284, 17868-17876 https://doi.org/10.1074/jbc.M900368200
- van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA and Lamers CB (2002) Malignancies in inflammatory bowel disease: fact or fiction? Scand J Gastroenterol Suppl, 48-53
- Yun HM, Park KR, Kim EC, Han SB, Yoon DY and Hong JT (2015) IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget 6, 9061-9072 https://doi.org/10.18632/oncotarget.3197
- Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S and Mori H (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94, 965-973 https://doi.org/10.1111/j.1349-7006.2003.tb01386.x
- Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694-702 https://doi.org/10.1016/0016-5085(90)90290-H
- Yang Y, Wang Z, Zhou Y, Wang X, Xiang J and Chen Z (2015) Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol 13, 146 https://doi.org/10.1186/s12957-015-0552-3
-
Khawar MB, Mukhtar M, Abbasi MH, Sheikh N (2017) IL-
$32{\theta}$ : a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity. Am J Transl Res 9, 4726-4737 -
Catalan V, Gomez-Ambrosi J, Rodriguez A et al (2017) IL-
$32{\alpha}$ -induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology 6, e1328338 - Sherman M and Klein A (2004) AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 40, 1465-1473 https://doi.org/10.1002/hep.20528
- Xu H, Zhang S, Pan X et al (2016) TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. Int Immunopharmacol 38, 233-237 https://doi.org/10.1016/j.intimp.2016.06.002
- Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22, 131-142 https://doi.org/10.1016/S1074-7613(04)00380-2
- Kudo M, Ogawa E, Kinose D et al (2012) Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. Respir Res 13, 19 https://doi.org/10.1186/1465-9921-13-19
- Dinarello CA and Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65 Suppl 3, iii61-64
- Pan X, Cao H, Lu J et al (2011) Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 48, 1573-1577 https://doi.org/10.1016/j.molimm.2011.03.012
- Moschen AR, Fritz T, Clouston AD et al (2011) Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53, 1819-1829 https://doi.org/10.1002/hep.24285
- Kang YH, Park MY, Yoon DY et al (2012) Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett 318, 226-233 https://doi.org/10.1016/j.canlet.2011.12.023
-
Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y, Zhu F (2018) Overexpression of interleukin-
$32{\alpha}$ promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol Rep. 39, 1155-1162 - Iliaz R, Akyuz U, Tekin D et al (2016) Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. Arab J Gastroenterol 17, 164-167 https://doi.org/10.1016/j.ajg.2016.10.002
- Kim DH, Park ES, Lee AR et al (2018) Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun 9, 3284 https://doi.org/10.1038/s41467-018-05782-5
- Sato M, Shames DS, Gazdar AF and Minna JD (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2, 327-343 https://doi.org/10.1097/01.JTO.0000263718.69320.4c
- Zeng Q, Li S, Zhou Y et al (2013) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65, 24-32 https://doi.org/10.1016/j.cyto.2013.09.017
- Sorrentino C and Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180, 769-779 https://doi.org/10.1164/rccm.200903-0400OC
- Wang Y, Yang Y, Zhu Y, Li L, Chen F and Zhang L (2017) Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer. Biomarkers 22, 165-170 https://doi.org/10.1080/1354750X.2016.1252956
- Yun J, Park MH, Son DJ et al (2018) IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell Death Dis 9, 306 https://doi.org/10.1038/s41419-018-0375-6
- Park JS, Choi SY, Lee JH et al (2013) Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr) 36, 493-503 https://doi.org/10.1007/s13402-013-0154-4
- Park JS, Lee S, Jeong AL et al (2014) Hypoxia-induced IL-32beta increases glycolysis in breast cancer cells. Cancer Lett 356, 800-808 https://doi.org/10.1016/j.canlet.2014.10.030
- Ainscough JS, Frank Gerberick G, Zahedi-Nejad M et al (2014) Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome. J Biol Chem 289, 35582-35592 https://doi.org/10.1074/jbc.M114.595686
- Yong HJ, Park JS, Lee Jeong A et al (2017) Von Hippel-Lindau regulates interleukin-32beta stability in ovarian cancer cells. Oncotarget 8, 69833-69846 https://doi.org/10.18632/oncotarget.19311
- Ternette N, Olde Nordkamp MJM, Muller J et al (2018) Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics 18, e1700465 https://doi.org/10.1002/pmic.201700465
- Lee S, Kim JH, Kim H et al (2010) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132, 410-420 https://doi.org/10.1111/j.1365-2567.2010.03377.x
- Lee S, Kim H, Kang JW et al (2011) The biflavonoid amentoflavone induces apoptosis via suppressing E7 expression, cell cycle arrest at sub-G(1) phase, and mitochondria-emanated intrinsic pathways in human cervical cancer cells. J Med Food 14, 808-816 https://doi.org/10.1089/jmf.2010.1428
- Goda C, Kanaji T, Kanaji S et al (2006) Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18, 233-240 https://doi.org/10.1093/intimm/dxh339
- Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW and Chopra AK (2009) Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal 21, 1085-1099 https://doi.org/10.1016/j.cellsig.2009.02.018
- Cui Y, Sun Z, Li X et al (2016) Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncol Lett 11, 693-698 https://doi.org/10.3892/ol.2015.3950
- Yamac D, Ayyildiz T, Coskun U et al (2008) Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol Res Pract 204, 527-536 https://doi.org/10.1016/j.prp.2008.01.002
- Konturek PC, Hartwich A, Zuchowicz M et al (2000) Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J Physiol Pharmacol 51, 737-749
- Lee S, Kim JH, Kim H et al (2011) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132, 410-420 https://doi.org/10.1111/j.1365-2567.2010.03377.x
- van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 132, 2050-2059 https://doi.org/10.1038/jid.2012.117
- Suga H, Sugaya M, Miyagaki T et al (2013) The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134, 1428-1435 https://doi.org/10.1038/jid.2013.488
- Cheon S, Lee JH, Park S et al (2011) Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem 286, 12049-12055 https://doi.org/10.1074/jbc.M110.159756
- Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781-790 https://doi.org/10.1038/nri1199
- Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR and Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19-29 https://doi.org/10.1016/S1074-7613(02)00333-3
- Park MH, Song MJ, Cho MC et al (2011) Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology 135, 63-72 https://doi.org/10.1111/j.1365-2567.2011.03513.x
- Smyth MJ, Cretney E, Takeda K et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193, 661-670 https://doi.org/10.1084/jem.193.6.661
- Screpanti V, Wallin RP, Grandien A and Ljunggren HG (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42, 495-499 https://doi.org/10.1016/j.molimm.2004.07.033
- Yun HM, Oh JH, Shim JH et al (2013) Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. Cell Death Dis 4, e640 https://doi.org/10.1038/cddis.2013.166
- Oh JH, Cho MC, Kim JH et al (2011) IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene 30, 3345-3359 https://doi.org/10.1038/onc.2011.52
- Qu Y, Taylor JL, Bose A and Storkus WJ (2011) Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther 18, 663-673 https://doi.org/10.1038/cgt.2011.37
- Ohmatsu H, Humme D, Gonzalez J et al (2017) IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression. Oncoimmunology 6, e1181237 https://doi.org/10.1080/2162402X.2016.1181237
- Chang CJ, Chien Y, Lu KH et al (2011) Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun 415, 245-251 https://doi.org/10.1016/j.bbrc.2011.10.024
- Moldenhauer A, Futschik M, Lu H et al (2011) Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. Eur J Immunol 41, 1774-1786 https://doi.org/10.1002/eji.201040986